References
- Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet 1984;2:1285–5
- Ron-El R, Herman A, Golan A, et al. Ultra-short gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-term GnRH-a protocol and menotropin alone. Fertil Steril 1992; 58:1164–8
- Urbancsek J, Witthaus E. Midluteal buserelin is superior to early follicular phase buserelin in com-bined gonadotropin-releasing hormone analogue and gonadotropin stimulation in in vitro fertilization. Fertil Steril 1996;65:966–71
- BouAbbas YY, Martin KA, Liberman RF, etal. Serum and follicular fluid hormone levels during in vitro fertilization after short or long course treatment with a gonadotropin-releasing hormone agonist. Fertil Steril 2001;75:694–9
- Moudgal RN, Rao AJ, Murthy GSRC, et al. Effect of intranasal administration of norethisterone and progesterone on pituitary and gonadal function in adult male and female bonnet monkeys (Macaca radiata). Fertil Steril 1985;44:120–4
- Anderson RE, Stein A, Paulson RJ, et al. Effects of norethindone on gonadotrophin and ovarian steroid secretion when used for cycle programming during in vitro fertilization. Fertil Steril 1990;54:96–101
- Nikas G, Drakakis P, Loutradis D, et al. Uterine pinopodes as markers of the `nidation window' in cycling women receiving exogenous oestradiol and progesterone. Hum Reprod 1995;10:1208–13
- Gonzales P, Maloul S, Giuffardi I, et al. The use of pro gestins for programming assisted reproductive cycles and gonadotropin-releasing hormone agonist flare-up protocols in older patients. Fertil Steril 1995; 63:249–51
- Stagner J, Yovich J. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985;92:385–93
- Howles C, Macnamee M, Edwards R. Follicular development and early luteal function of conception and non-conceptional cycles after human in-vitro fertilization: endocrine correlates. Hum Reprod 1987; 2:17–21
- Tulppala M, Stenman U, Cacciatore B, et al. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br J Obstet Gynaecol 1993;100:348–52
- Penzias AS. Luteal phase support. Fertil Steril 2002; 77:318–23
- Engmann L, Maconochie N, Bekir J, et al. Proges-togen therapy during pituitary desensitization with gonadotropin-releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study. Am J Obstet Gynecol 1999;181: 576–82
- Al-Mizyen E, Sabatini L, Lower AM, et al. Does pre-treatment with pro gestogen or oral contraceptive pills in low responders followed by the GnRH-a flare protocol improve the outcome of IVF-ET? J Assist Reprod Genet 2000;17:140–6
- Ditkoff EC, Sauer MV. A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Hum Reprod 1996;11:1035–7
- Aston K, Arthur GM, Jenkins JM. Progesterone therapy may prevent the development of functional ovarian cysts during pituitary down-regulation with GnRH agonists. BrJ Obstet Gynaecol1995;102:835–7
- Hamberger L, Lundin K, Sjögren A, etal. Indications for intracytoplasmic sperm injection. Hum Reprod 1998;13:128–33
- Psychoyos A, Nikas G. Uterine pinopodes as marker ofuterine receptivity. Assist Reprod Rev 1994;4:26–32
- Develioglu OH, Hsiu JG, Nikas JP, etal. Endometrial estrogen and progesterone receptor and pinopode expression in stimulated cycles of oocyte donors. Fertil Steril 1999;71:1040–7